Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| 89R8229 JTZ-F | ||
| By: Oliverson | H.B. No. 3086 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to requirements for pharmaceutical drug manufacturers to | |
| report prescription drug costs. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Section 441.0051, Health and Safety Code, is | |
| amended to read as follows: | |
| Sec. 441.0051. ANNUAL REPORT. (a) Not later than the 15th | |
| day of each calendar year, a pharmaceutical drug manufacturer shall | |
| submit a report to the department stating the current wholesale | |
| acquisition cost information for the United States Food and Drug | |
| Administration-approved prescription drugs sold in or into this | |
| state by that manufacturer. | |
| (b) For a prescription drug with a wholesale acquisition | |
| cost increase of 40 percent or more over the drug's wholesale | |
| acquisition cost in the preceding three calendar years or 15 | |
| percent or more in the preceding calendar year, a pharmaceutical | |
| drug manufacturer shall include in the annual report required under | |
| Subsection (a): | |
| (1) information on whether the prescription drug is a | |
| brand name drug or generic version of a brand name drug; | |
| (2) a statement on each factor that caused the | |
| increase in the wholesale acquisition cost and an explanation of | |
| the impact of each factor on the cost; | |
| (3) aggregate, research, and development costs as | |
| filed with United States Securities and Exchange Commission on Form | |
| 10-K for the most recent calendar year for which final audit data is | |
| available; | |
| (4) the name of each of the manufacturer's | |
| prescription drugs the United States Food and Drug Administration | |
| approved in the previous three calendar years; and | |
| (5) the name of each of the manufacturer's | |
| prescription drugs that lost patent exclusivity in the United | |
| States in the previous three calendar years. | |
| (c) The information a pharmaceutical drug manufacturer | |
| submits to the department under Subsections (a) and (b) must be | |
| consistent with the information the manufacturer includes in the | |
| manufacturer's annual consolidated report filed with the United | |
| States Securities and Exchange Commission on Form 10-K or any other | |
| public disclosure. | |
| SECTION 2. Section 441.0054, Health and Safety Code, is | |
| amended to read as follows: | |
| Sec. 441.0054. PUBLICATION OF COST INCREASE INFORMATION. | |
| Not later than the 60th day after receipt of the report submitted | |
| under Section 441.0051 [ |
|
| publish the required cost increase information [ |
|
| Internet website. | |
| SECTION 3. Section 441.0102(a), Health and Safety Code, is | |
| amended to read as follows: | |
| (a) The department shall [ |
|
| penalty against a person who violates this chapter or a rule adopted | |
| under this chapter. | |
| SECTION 4. Section 441.0053, Health and Safety Code, is | |
| repealed. | |
| SECTION 5. As soon as practicable after the effective date | |
| of this Act, the executive commissioner of the Health and Human | |
| Services Commission shall adopt rules necessary to implement the | |
| changes in law made by this Act. | |
| SECTION 6. This Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.